Birthe Lund

3.2k total citations
73 papers, 2.3k citations indexed

About

Birthe Lund is a scholar working on Oncology, Reproductive Medicine and Surgery. According to data from OpenAlex, Birthe Lund has authored 73 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 22 papers in Reproductive Medicine and 11 papers in Surgery. Recurrent topics in Birthe Lund's work include Ovarian cancer diagnosis and treatment (22 papers), Education, Healthcare and Sociology Research (10 papers) and Lung Cancer Research Studies (9 papers). Birthe Lund is often cited by papers focused on Ovarian cancer diagnosis and treatment (22 papers), Education, Healthcare and Sociology Research (10 papers) and Lung Cancer Research Studies (9 papers). Birthe Lund collaborates with scholars based in Denmark, Netherlands and Spain. Birthe Lund's co-authors include Ole Hansen, Jaap Verweij, Heine H. Hansen, J.P. Neijt, G.J. Creemers, Karen Theilade, Mads Hansen, N. Thatcher, Heather Anderson and Jackie Walling and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Birthe Lund

60 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Birthe Lund Denmark 22 1.1k 782 640 623 548 73 2.3k
Alexander Kennedy United States 34 947 0.9× 1.3k 1.7× 684 1.1× 795 1.3× 451 0.8× 99 3.5k
Hans‐Joachim Lück Germany 28 1.9k 1.7× 704 0.9× 395 0.6× 402 0.6× 572 1.0× 67 2.9k
Holger W. Hirte Canada 20 978 0.9× 433 0.6× 763 1.2× 216 0.3× 430 0.8× 46 2.0k
Carolyn Krasner United States 26 1.0k 0.9× 1.2k 1.5× 627 1.0× 463 0.7× 528 1.0× 107 2.5k
Tate Thigpen United States 26 1.2k 1.1× 1.2k 1.5× 493 0.8× 754 1.2× 601 1.1× 49 2.9k
Uziel Beller Israel 25 723 0.7× 803 1.0× 971 1.5× 411 0.7× 182 0.3× 68 3.0k
Lainie P. Martin United States 29 1.7k 1.5× 959 1.2× 1.2k 1.9× 278 0.4× 414 0.8× 100 3.2k
Volker Möbus Germany 26 1.2k 1.1× 422 0.5× 493 0.8× 231 0.4× 312 0.6× 117 2.2k
Eirini Pectasides Greece 24 621 0.6× 600 0.8× 617 1.0× 493 0.8× 388 0.7× 49 1.8k
Michael Teneriello United States 17 1.1k 1.0× 1.6k 2.0× 487 0.8× 535 0.9× 308 0.6× 33 2.3k

Countries citing papers authored by Birthe Lund

Since Specialization
Citations

This map shows the geographic impact of Birthe Lund's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Birthe Lund with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Birthe Lund more than expected).

Fields of papers citing papers by Birthe Lund

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Birthe Lund. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Birthe Lund. The network helps show where Birthe Lund may publish in the future.

Co-authorship network of co-authors of Birthe Lund

This figure shows the co-authorship network connecting the top 25 collaborators of Birthe Lund. A scholar is included among the top collaborators of Birthe Lund based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Birthe Lund. Birthe Lund is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lund, Birthe. (2008). Kreativitet og innovation. VBN Forskningsportal (Aalborg Universitet).
2.
Lund, Birthe. (2008). Portfolio i et lærings- og uddannelsesperspektiv. 2 indexed citations
3.
Lund, Birthe. (2003). It og læringsperspektiver. 1 indexed citations
4.
Underhill, Craig, Francis Parnis, Martin Highley, et al.. (2001). Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Anti-Cancer Drugs. 12(8). 647–652. 19 indexed citations
5.
Nielsen, Svend Erik, Jesper Zeuthen, Birthe Lund, et al.. (2000). Phase I Study of Single, Escalating Doses of a Superantigen–Antibody Fusion Protein (PNU-214565) in Patients With Advanced Colorectal or Pancreatic Carcinoma. Journal of Immunotherapy. 23(1). 146–153. 28 indexed citations
6.
Aamdal, Steinar, et al.. (2000). Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG). Cancer Chemotherapy and Pharmacology. 45(1). 85–88. 10 indexed citations
7.
Strauss, Gitte, Birthe Lund, Mogens Hansen, & Heine H. Hansen. (1997). Phase II Trial of High-Dose Cisplatin Plus Ifosfamide as First-Line Followed by Carboplatin as Second-Line Treatment in Epithelial Ovarian Carcinoma. Gynecologic Oncology. 66(1). 66–70. 3 indexed citations
8.
McLeod, Howard L., et al.. (1996). Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. European Journal of Cancer. 32(9). 1518–1522. 22 indexed citations
9.
Lausten, Gunnar Schwarz, Jensen Pk, Torben Schiødt, & Birthe Lund. (1996). Local recurrences in giant cell tumour of bone. International Orthopaedics. 20(3). 172–176. 71 indexed citations
10.
Lund, Birthe, et al.. (1995). Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anti-Cancer Drugs. 6(Supplement 6). 61–62. 42 indexed citations
11.
Creemers, G.J., Birthe Lund, & Jaap Verweij. (1994). Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treatment Reviews. 20(1). 73–96. 218 indexed citations
12.
Lund, Birthe, M. Ryberg, René Horsleben Petersen, et al.. (1994). Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung c. Annals of Oncology. 5(9). 852–853. 29 indexed citations
13.
Anderson, Heather, Birthe Lund, Flemming W. Bach, et al.. (1994). Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.. Journal of Clinical Oncology. 12(9). 1821–1826. 310 indexed citations
14.
Verweij, Jaap, Birthe Lund, Jos H. Beijnen, et al.. (1993). Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Annals of Oncology. 4(8). 673–678. 110 indexed citations
15.
Lund, Birthe, Paul E.G. Kristjansen, & Heine H. Hansen. (1993). Clinical and preclinical activity of 2′,2′- difluorodeoxycytidine (gemcitabine). Cancer Treatment Reviews. 19(1). 45–55. 119 indexed citations
16.
Levin, Leslie, Birthe Lund, & A. Peter M. Heintz. (1993). An overview of multi-variate analyses of prognostic variables with special reference to the role of cytoreductive surgery. Annals of Oncology. 4. S23–S29. 23 indexed citations
17.
Lund, Birthe & Peace Ossom Williamson. (1991). Prognostic factors for overall survival in patients with advanced ovarian carcinoma. Annals of Oncology. 2(4). 281–287. 17 indexed citations
18.
Lund, Birthe, Henrik Klem Thomsen, & Jens Olsen. (1991). Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications. Apmis. 99(1-6). 353–358. 32 indexed citations
19.
Lund, Birthe, M Hansen, Heine H. Hansen, et al.. (1990). A randomized study of sequential versus alternating combination chemotherapy in advanced ovarian carcinoma. Annals of Oncology. 1(2). 134–140. 6 indexed citations
20.
Lund, Birthe, Flemming Hansen, Mogens Hansen, & Heine H. Hansen. (1987). Phase II study of 1,2,4-triglycidylurazol (TGU) previously untreated and treated patients with small cell lung cancer. European Journal of Cancer and Clinical Oncology. 23(7). 1031–1033. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander Kennedy Breakdown of academic impact, for papers by Hans‐Joachim Lück Breakdown of academic impact, for papers by Holger W. Hirte Breakdown of academic impact, for papers by Carolyn Krasner Breakdown of academic impact, for papers by Tate Thigpen Breakdown of academic impact, for papers by Uziel Beller Breakdown of academic impact, for papers by Lainie P. Martin Breakdown of academic impact, for papers by Volker Möbus Breakdown of academic impact, for papers by Eirini Pectasides Breakdown of academic impact, for papers by Michael Teneriello
Rankless by CCL
2026